Article Text

Download PDFPDF
Potential for biosimilars in rheumatology in Africa
  1. Mohamed Hassan Abu-Zaid1,
  2. Adewale Adebajo2,3,
  3. Yasser El Miedany4,5
  1. 1 Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Tanta, Egypt
  2. 2 Rheumatology and Health Services Research, The University of Sheffield, Sheffield, UK
  3. 3 NIHR Sheffield Clinical Research Facility, Sheffield, UK
  4. 4 Rheumatology, Canterbury Christ Church College, Chatham, UK
  5. 5 Rheumatology and Rehabilitation, Ain Shams University Faculty of Medicine, Cairo, Egypt
  1. Correspondence to Dr Mohamed Hassan Abu-Zaid, Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Tanta, 6632110, Egypt; drmhassan113{at}


Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology.

  • Biosimilar Pharmaceuticals
  • Biological Therapy
  • Therapeutics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Josef S Smolen

  • Contributors The manuscript was written by MHA-Z and MHA-Z, with contribution from YEM and AA. All authors contributed in the manuscript writing, reading and approval of the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.